Pulmo BioTech Inc. was the name given to the surviving corporation of the merger on February 29, 2008 of Lumen Medical Inc., a non-public Florida corporation ("Lumen"), with and into Acorn Acquisition Corp., a public Delaware corporation ("Acorn"). We were organized pursuant to the laws of the State of Delaware on July 20, 2006, with an authorized capital of $2,500 divided into 250,000,000 shares of common stock, par value $0.0001 per share, by our parent corporation, Syntony Group Inc., a public Utah corporation ("Syntony"), for the sole purpose of enabling Syntony to merge on October 1, 2006 with and into Acorn, thus effecting a reincorporation from Utah to Delaware and changing the symbol of the public company from STOY to ACAQ. In connection with the merger of Lumen with and into Acorn, our symbol was changed again, from ACAQ to PLMO. The reincorporation of Syntony from Utah to Delaware reduced the number of authorized shares from 800,000,000 shares of Syntony common stock to 250,000,000 shares of Acorn common stock and reduced the number of issued and outstanding shares from 13,723,462 shares of Syntony common stock to 1,372,574 shares of Acorn common stock. Pursuant to the merger of Lumen with and into Acorn, an aggregate of 51,250,000 shares of our common stock were issued to the former shareholders of Lumen, thereby increasing the number of issued and outstanding shares from 1,372,574 to 52,622,574 shares of PLMO common stock.